Sarepta Therapeutics (SRPT) Tops Q4 EPS by 4c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sarepta Therapeutics (SRPT) PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path & DMD Gene Therapies Emerge in 2018'
March 2, 2018 6:21 AM ESTNomura/Instinet raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $84.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.
Analyst Christopher Marai notes a positive outlook on the shares, as SRPT reported fourth quarter earning per share and... More
